ERR2598164
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 4
- umap1_2d
- -2.085066918
- umap2_2d
- -1.048292894
- umap1_3d
- -4.126170627
- umap2_3d
- 3.420715578
- umap3_3d
- -1.559826763
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.660
- MYC_TARGETS_V2+0.660
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.570
- WNT_BETA_CATENIN_SIGNALING+0.410
- MITOTIC_SPINDLE+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.350
- MTORC1_SIGNALING+0.330
- TGF_BETA_SIGNALING+0.290
- ANDROGEN_RESPONSE+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- PANCREAS_BETA_CELLS-0.340
- INTERFERON_GAMMA_RESPONSE-0.280
- OXIDATIVE_PHOSPHORYLATION-0.280
- TNFA_SIGNALING_VIA_NFKB-0.280
- HEDGEHOG_SIGNALING-0.260
- KRAS_SIGNALING_UP-0.230
- COMPLEMENT-0.220
- HEME_METABOLISM-0.220
- INFLAMMATORY_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598180 | fetal | fetal | 0.965 |
| 2 | ERR2598165 | fetal | fetal | 0.958 |
| 3 | ERR2598166 | fetal | fetal | 0.940 |
| 4 | ERR2598181 | fetal | fetal | 0.922 |
| 5 | ERR2598170 | fetal | fetal | 0.908 |
| 6 | ERR2598184 | fetal | fetal | 0.898 |
| 7 | ERR2598171 | fetal | fetal | 0.854 |
| 8 | DF749F48-6A86-4640-9C62-31B4A7C5D1A9 | — | — | 0.852 |
| 9 | BS_TZ5D0A7R | Supratentorial Ependymoma | — | 0.851 |
| 10 | BS_Z7890YNR | EPN | Supratentorial EPN | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.660 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.660 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |